Nxera Pharma Ltd
Tokyo, Tokyo, Japan · Biotechnology, Pharmaceutical
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnershi
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Tokyo, Tokyo, Japan
- Employees
- 390
- Industries
- Biotechnology, Pharmaceutical
- Website
- www.nxera.life
- Company page
Recent activity at Nxera Pharma Ltd
- : Nxera Pharma secured a $10 million milestone payment from Neurocrine Biosciences following IND acceptance for NBI-1117567 in a Phase 2 study. This funding will enhance Nxera's drug development initiatives.
- : Nxera Pharma has participated in a Series A financing for NewCo, a company it co-founded, to accelerate preclinical studies of a GPCR-targeted program. Nxera is eligible for up to $275 million in milestone payments.
- : Nxera Pharma Appoints Kiyoshi Kaneko as Chief Commercial Officer and Promotes Mariko Nakafuji to Chief Legal Officer
About Nxera Pharma Ltd: questions and answers
What does Nxera Pharma Ltd do?
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnershi
Where is Nxera Pharma Ltd headquartered?
Nxera Pharma Ltd is headquartered in Tokyo, Tokyo, Japan.
How many employees does Nxera Pharma Ltd have?
Nxera Pharma Ltd has about 390 employees.
What is the latest news on Nxera Pharma Ltd?
On Aug 26, 2026, Nxera Pharma secured a $10 million milestone payment from Neurocrine Biosciences following IND acceptance for NBI-1117567 in a Phase 2 study. This funding will enhance Nxera's drug development initiatives.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy